Managing antiretroviral-associated liver disease

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue SUPPL. 1, 2003, Pages

  Dieterich, Douglas ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Efavirenz; Hepatitis C; Nevirapine; Non nucleoside reverse transcriptase inhibitors; Nucleoside analogs; Protease inhibitors

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; INTERFERON; LAMIVUDINE; METFORMIN; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL FEATURE; COMORBIDITY; CONFERENCE PAPER; DRUG CHOICE; DRUG INDICATION; DRUG WITHDRAWAL; GLUCOSE HOMEOSTASIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; HYPOTENSION; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPOATROPHY; LIVER DISEASE; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER TOXICITY; MEDICAL DECISION MAKING; MITOCHONDRIAL TOXICITY; MULTIVARIATE ANALYSIS; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RETROSPECTIVE STUDY; SIDE EFFECT; STEATOHEPATITIS; STEATOSIS; TREATMENT PLANNING; VIRUS HEPATITIS; WEIGHT REDUCTION;

HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INSULIN RESISTANCE; LIVER DISEASES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0141793145     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200309011-00006     Document Type: Conference Paper

References (29)

1. Darby SC, Ewart DW, Giangrande PLF, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350:1245-1231.
2. Centers for Disease Control and Prevention. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR 1999;48(No.RR-10):32-34.
3. Melvin DC, Lee JK, Belsey E, et al. The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy. AIDS 2000;14:463-446.
4. den Brinker M, Wit FWNM, Wertheim-van Dillen PME, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000;14:2895-2902.
5. Greub G, Lederberger B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000;356:1800-1805.
6. Monforte Ad'A, Bugarini R, Pezzotti P, et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. JAIDS 2001;28:114-123.
7. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Inf Dis 2001;33:240-247.
8. Núñez M, Lana R, Mendoza JL, et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. JAIDS 2001;27:426-431.
9. Manning FJ, Swartz M, editors. Review of the Fialuridine (FIAU) Clinical Trials. Washington DC: National Academy Press, 1995.
10. Burkus G, Hitchcock MJM, Cihlar T. Mitochondrial toxicity of NRTIs: in vitro assessment and comparison with tenofovir [abstract 708-T]. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, U.S.A., 24-28 February 2002.
11. Burkus G, Hitchcock MJM, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46:716-723.
12. Alan B, Droogan O, Nolan N, et al. Detection of a common deletion in the mitochondrial DNA of patients with chronic hepatitis C virus (HCV) infection and hepatic steatosis [abstract #259]. Hepatology 32 pt. 2, October 2000.
13. Tilig H, Diehl AM. Cytokines in alcoholic and non-alcoholic steatohepatitis. N Engl J Med 2000;343:1467-1475.
14. Sulkowski M, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
15. Bartlett J. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor [abstract 19]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, U.S.A., 4-8 February 2001.
16. Sulkowski M, Thomas D, Mehta S, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002;35:182-189.
17. Reisler R, Servoss JC, Sherman KE, et al. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials [abstract 43]. Presented at the 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, 8-11 July 2001.
18. Palmon R, Koo BCA, Shoultz DA, et al. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. JAIDS 2002;29:340-345.
19. Dieterich D, Stern J, Robinson P, et al. Analyses of four key clinical trials to assess the risk of hepatotoxicity with nevirapine: correlation with CD4+ levels, hepatitis B & C seropositivity and baseline liver function tests [abstract 44]. Presented at the 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 8-11 July 2001.
20. Martínez E, Blanco JL, Arniaz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001;15:1261-1268.
21. Puoti M, Patroni A, Pan A, et al. Hepatotoxicity associated with non nucleoside reverse transcriptase inhibitors (NNRTI) in 427 adults infected with human immunodeficiency virus [abstract P129]. Presented at the 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, Athens, Greece, 28-31 October, 2001.
22. González de Requena D, Nuñez M, Jimenez-Nácher I, et al. Higher nevirapine plasma levels correlated with the development of hepatic injury [abstract LB P22]. Presented at the 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 8-11 July 2001.
23. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001;15:F11-F18.
24. Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus co-infected patients undergoing antiretroviral therapy. JAIDS 2001;27:245-250.
25. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor [abstract 672]. Presented at the 6th Conference on Retroviruses and Opportunistic Infection, Chicago, IL, U.S.A., 31 January-4 February 1999.
26. Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome. A randomised controlled trial. JAMA 2000;284:472-477.
27. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001;358:893-894.
28. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-1364.
29. Domingo P, Matías-Guiu X, Pujol RM, et al. Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy. J Inf Dis 2001;184:1197-1201.